Evidence map›Paper›PMID 36451828›Full record

ReviewFrontiers in immunology2022

Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.

Wu Ge, Yuqian Dong, Yao Deng, Lujuan Chen, Juan Chen, Muqi Liu, Jianmin Wu, Wei Wang, Xiaoqian Ma

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wu GeCell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, China.
Yuqian DongDepartment of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
Yao DengDepartment of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
Lujuan ChenDepartment of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
Juan ChenDepartment of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
Muqi LiuDepartment of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
Jianmin WuDepartment of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
Wei WangCell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, China.
Xiaoqian MaCell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-specific T cells (TSTs) are essential components for the success of personalized tumor-infiltrating lymphocyte (TIL)-based adoptive cellular therapy (ACT). Therefore, the selection of a common biomarker for screening TSTs in different tumor types, followed by

Indexed as

NeoplasmsT-LymphocytesBiomarkersHumansLymphocyte CountLymphocytes, Tumor-InfiltratingBiomarkersadoptive cellular therapybiomarkercancer treatmenttumor infiltration lymphocytetumor specific T cell

Identifiers

PMID36451828
PMCPMC9702804
OpenAlexW4309039962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.